plasmid dnas encoding human genes Search Results


plasmid dnas encoding human genes  (GenScript corporation)
90
GenScript corporation plasmid dnas encoding human genes
Plasmid Dnas Encoding Human Genes, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid dnas encoding human genes/product/GenScript corporation
Average 90 stars, based on 1 article reviews
plasmid dnas encoding human genes - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
plasmid dnas encoding human gp100  (Sangon Biotech)
90
Sangon Biotech plasmid dnas encoding human gp100
Schematic diagram of the action principle of IPMN‐GC. i) The target genes <t>gp100</t> and CCL21 are transfected into E. coli by genetic engineering to extract OMV (G OMV and C OMV ) which carries the target protein. ii) Using MN to load G OMV and C OMV respectively to improve the transdermal efficiency and release of OMV. iii) The OMV is negatively charged, and the iontophoresis technology is used to promote the charged OMV to pass through the tissue barrier into the body through a low‐intensity DC electric field, thereby improving the transdermal penetration ability of the drug. v) The uptake of G OMV by local skin DC cells can promote its maturation. After 12 h, the delivery of C OMV enhances the migration of DC cells to lymph nodes through CCR7‐CCL21 after lymph node enrichment, thereby improving the antigen presentation of DCs to T cells and enhancing antitumor immune effects.
Plasmid Dnas Encoding Human Gp100, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid dnas encoding human gp100/product/Sangon Biotech
Average 90 stars, based on 1 article reviews
plasmid dnas encoding human gp100 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
plasmids encoding c-dnas of human -pix ch domain deleted mutant  (Kazusa Genome Technologies)
90
Kazusa Genome Technologies plasmids encoding c-dnas of human -pix ch domain deleted mutant
Schematic diagram of the action principle of IPMN‐GC. i) The target genes <t>gp100</t> and CCL21 are transfected into E. coli by genetic engineering to extract OMV (G OMV and C OMV ) which carries the target protein. ii) Using MN to load G OMV and C OMV respectively to improve the transdermal efficiency and release of OMV. iii) The OMV is negatively charged, and the iontophoresis technology is used to promote the charged OMV to pass through the tissue barrier into the body through a low‐intensity DC electric field, thereby improving the transdermal penetration ability of the drug. v) The uptake of G OMV by local skin DC cells can promote its maturation. After 12 h, the delivery of C OMV enhances the migration of DC cells to lymph nodes through CCR7‐CCL21 after lymph node enrichment, thereby improving the antigen presentation of DCs to T cells and enhancing antitumor immune effects.
Plasmids Encoding C Dnas Of Human Pix Ch Domain Deleted Mutant, supplied by Kazusa Genome Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmids encoding c-dnas of human -pix ch domain deleted mutant/product/Kazusa Genome Technologies
Average 90 stars, based on 1 article reviews
plasmids encoding c-dnas of human -pix ch domain deleted mutant - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Schematic diagram of the action principle of IPMN‐GC. i) The target genes gp100 and CCL21 are transfected into E. coli by genetic engineering to extract OMV (G OMV and C OMV ) which carries the target protein. ii) Using MN to load G OMV and C OMV respectively to improve the transdermal efficiency and release of OMV. iii) The OMV is negatively charged, and the iontophoresis technology is used to promote the charged OMV to pass through the tissue barrier into the body through a low‐intensity DC electric field, thereby improving the transdermal penetration ability of the drug. v) The uptake of G OMV by local skin DC cells can promote its maturation. After 12 h, the delivery of C OMV enhances the migration of DC cells to lymph nodes through CCR7‐CCL21 after lymph node enrichment, thereby improving the antigen presentation of DCs to T cells and enhancing antitumor immune effects.

Journal: Small Science

Article Title: Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy

doi: 10.1002/smsc.202300126

Figure Lengend Snippet: Schematic diagram of the action principle of IPMN‐GC. i) The target genes gp100 and CCL21 are transfected into E. coli by genetic engineering to extract OMV (G OMV and C OMV ) which carries the target protein. ii) Using MN to load G OMV and C OMV respectively to improve the transdermal efficiency and release of OMV. iii) The OMV is negatively charged, and the iontophoresis technology is used to promote the charged OMV to pass through the tissue barrier into the body through a low‐intensity DC electric field, thereby improving the transdermal penetration ability of the drug. v) The uptake of G OMV by local skin DC cells can promote its maturation. After 12 h, the delivery of C OMV enhances the migration of DC cells to lymph nodes through CCR7‐CCL21 after lymph node enrichment, thereby improving the antigen presentation of DCs to T cells and enhancing antitumor immune effects.

Article Snippet: Plasmid DNAs (pDNAs) encoding human gp100 (gp100) and mouse CC chemokine ligand 21 (CCL21) (Sangon Biotechnology Inc., China), respectively, were transformed into E. coli by heat shock method, forming gp100 transformed E. coli (G‐ E. coli ) and CCL21 transformed E. coli (C‐ E. coli ).

Techniques: Transfection, Migration, Immunopeptidomics

Construction and characterization of G OMV and C OMV . a) Transformation of E. coli by pDNAs encoding target genes and the secretion of C OMV , G OMV , and OMVs. b) TEM images of OMV derived from ancestral E. coli , G OMV , and C OMV . Scale bar: 200 nm. c,d) The size distribution and zeta potentials of OMVs, G OMV , and C OMV . e,f) The identification of gp100 and CCL21 proteins in the tested samples.

Journal: Small Science

Article Title: Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy

doi: 10.1002/smsc.202300126

Figure Lengend Snippet: Construction and characterization of G OMV and C OMV . a) Transformation of E. coli by pDNAs encoding target genes and the secretion of C OMV , G OMV , and OMVs. b) TEM images of OMV derived from ancestral E. coli , G OMV , and C OMV . Scale bar: 200 nm. c,d) The size distribution and zeta potentials of OMVs, G OMV , and C OMV . e,f) The identification of gp100 and CCL21 proteins in the tested samples.

Article Snippet: Plasmid DNAs (pDNAs) encoding human gp100 (gp100) and mouse CC chemokine ligand 21 (CCL21) (Sangon Biotechnology Inc., China), respectively, were transformed into E. coli by heat shock method, forming gp100 transformed E. coli (G‐ E. coli ) and CCL21 transformed E. coli (C‐ E. coli ).

Techniques: Transformation Assay, Derivative Assay

Fabrication and characterization of IPMN‐G and IPMN‐C. a) The composition and structure of MNs. b 1 ) SEM images of MNs from different angles. b 2 ) SEM image of MN surface. b 3 ) Porosity of the MNs made from the two stock solutions of raw material mixed crosslinking agent and pore‐foaming agent in different ratios. c) Loading of OMVs in MNs with different porosity percentages. d) SEM image of MN‐OMV. e) EDS analysis of MN‐OMV. f,g) Characterization of the mechanical strength of MN samples: f) compressive fracture force of MNs; g) compression force versus displacement of MNs penetrating skin corneum. h) Schematic of the 3D scaffold model for in vitro tests. i) gp100 release profiles without or with IP ( n = 5). j) CCL21 release profiles without or with IP ( n = 5). k), Cell viability of BMDCs treated with IPMN under different electric intensities (voltage: 10, 20, 30, 40, 50, 60 V; working time: 30 s). (* p < 0.05, ** p < 0.01, *** p < 0.001).

Journal: Small Science

Article Title: Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy

doi: 10.1002/smsc.202300126

Figure Lengend Snippet: Fabrication and characterization of IPMN‐G and IPMN‐C. a) The composition and structure of MNs. b 1 ) SEM images of MNs from different angles. b 2 ) SEM image of MN surface. b 3 ) Porosity of the MNs made from the two stock solutions of raw material mixed crosslinking agent and pore‐foaming agent in different ratios. c) Loading of OMVs in MNs with different porosity percentages. d) SEM image of MN‐OMV. e) EDS analysis of MN‐OMV. f,g) Characterization of the mechanical strength of MN samples: f) compressive fracture force of MNs; g) compression force versus displacement of MNs penetrating skin corneum. h) Schematic of the 3D scaffold model for in vitro tests. i) gp100 release profiles without or with IP ( n = 5). j) CCL21 release profiles without or with IP ( n = 5). k), Cell viability of BMDCs treated with IPMN under different electric intensities (voltage: 10, 20, 30, 40, 50, 60 V; working time: 30 s). (* p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: Plasmid DNAs (pDNAs) encoding human gp100 (gp100) and mouse CC chemokine ligand 21 (CCL21) (Sangon Biotechnology Inc., China), respectively, were transformed into E. coli by heat shock method, forming gp100 transformed E. coli (G‐ E. coli ) and CCL21 transformed E. coli (C‐ E. coli ).

Techniques: Raw Material, Foaming, In Vitro

Transdermal delivery of gp100 and CCL21 proteins by IPMN‐G and IPMN‐C in vitro. a) Schematic representation of the facilitation in transdermal delivery of gp100 and CCL21 by IPMN‐G or IPMN‐C. b) CLSM images of skin treated by the tested samples for 30 min through topical application. Scale bar; 200 μm. c) Quantification of the amounts of permeated gp100 protein (c 1 ) and CCL21 protein (c 2 ) in vitro ( n = 3). d) Quantification of the amounts of gp100 (d 1 ) and CCL21 proteins (d 2 ) in skins in vitro ( n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001).

Journal: Small Science

Article Title: Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program that Stimulates Transcutaneous Vaccination for Cancer Immunotherapy

doi: 10.1002/smsc.202300126

Figure Lengend Snippet: Transdermal delivery of gp100 and CCL21 proteins by IPMN‐G and IPMN‐C in vitro. a) Schematic representation of the facilitation in transdermal delivery of gp100 and CCL21 by IPMN‐G or IPMN‐C. b) CLSM images of skin treated by the tested samples for 30 min through topical application. Scale bar; 200 μm. c) Quantification of the amounts of permeated gp100 protein (c 1 ) and CCL21 protein (c 2 ) in vitro ( n = 3). d) Quantification of the amounts of gp100 (d 1 ) and CCL21 proteins (d 2 ) in skins in vitro ( n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: Plasmid DNAs (pDNAs) encoding human gp100 (gp100) and mouse CC chemokine ligand 21 (CCL21) (Sangon Biotechnology Inc., China), respectively, were transformed into E. coli by heat shock method, forming gp100 transformed E. coli (G‐ E. coli ) and CCL21 transformed E. coli (C‐ E. coli ).

Techniques: In Vitro